Ex-GSK Melanoma Therapy Secures EU Approval For Novartis
This article was originally published in Scrip
Executive Summary
Novartis AG has been granted European approval for two products it picked up via a $20bn mega deal transaction with GlaxoSmithKline plc, a deal which closed in March this year.